Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics

Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal target recognition module of a conventional antibody is composed of two non-covalently associated variable domains (VH an...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Peter Bannas, Julia Hambach, Friedrich Koch-Nolte
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-11-01
Subjects:	nanobodies heavy chain antibodies antitumor therapeutics nanobody-conjugates nanobody fusion proteins sortagging of nanobodies
Online Access:	http://journal.frontiersin.org/article/10.3389/fimmu.2017.01603/full